

# Hearing Loss and Urinary *trans,trans*-Muconic Acid (*t,t*-MA) in 6- to 19-Year-Old Participants of NHANES 2017–March 2020

Rae T. Benedict <sup>1,\*</sup>, Franco Scinicariello <sup>1</sup>, Henry G. Abadin <sup>1</sup>, Gregory M. Zarus <sup>1</sup> and Roberta Attanasio <sup>2</sup>

**Table S1.** Logistic regression ORs (95% CI) of slight hearing loss outcomes and urinary *t,t*-MA<sup>a</sup> levels for US participants 6–19 year-old participants of NHANES 2017–March 2020.

	Slight Speech Frequency Hearing Loss >15dB (SFHL)	Slight High Frequency Hearing Loss >15dB (HFHL)	Any Slight Hearing Loss >15dB
	Crude Model	Crude Model	Crude Model
Case/control, <i>n</i>	48/636	77/604	89/597
<i>t,t</i> -MA (natural log)	1.47 (1.01, 2.12)*	1.47 (1.09, 1.99)*	1.41 (1.05, 1.91)*
<i>t,t</i> -MA doubling	1.30 (1.01, 1.68)*	1.31 (1.06, 1.61)*	1.27 (1.03, 1.56)*
<i>t,t</i> -MA Quartiles (ng/mL)			
Q1: ≤ 29.17	1 (referent)	1 (referent)	1 (referent)
Q2: 29.18-61.51	0.76 (0.22, 2.61)	1.20 (0.39, 3.71)	0.94 (0.36, 2.46)
Q3: 61.52-156.50	0.65 (0.16, 2.62)	2.00 (0.44, 9.11)	1.74 (0.48, 6.37)
Q4: >156.50	3.08 (1.07, 8.87)*	4.11 (1.35, 12.53)*	3.25 (1.20, 8.80)*
<i>p</i> -trend	0.01*	0.0046*	0.007*

<sup>a</sup> *t,t*-MA has been weighted using specific sample weights for the subsample, WTVOC2PP, as recommended by NCHS [21].

Crude model does not adjust for any confounders. \*Indicates associations with statistical significance (*p*<0.05).

**Table S2.** Multivariate logistic regression adjusted ORs (95% CI) of mild hearing loss outcomes and urinary *t,t*-MA<sup>a</sup> quartiles for US participants 6–19 year-old participants of NHANES 2017–March 2020.

	Mild Speech Frequency Hearing Loss >20dB (SFHL)		Mild High Frequency Hearing Loss >20dB (HFHL)		Any Mild Hearing Loss >20dB	
	Model 1	Model 2	Model 1	Model 2	Model 1	Model 2
Case/control, <i>n</i>	20/664	17/572	31/650	28/557	34/652	31/559
<i>t,t</i> -MA Quartiles (ng/mL)						
Q1: ≤ 29.17	1 (referent)	1 (referent)	1 (referent)	1 (referent)	1 (referent)	1 (referent)
Q2: 29.18-61.51	1.06 (0.12, 9.46)	1.29 (0.09, 18.93)	0.97 (0.20, 4.69)	1.16 (0.16, 8.38)	0.97 (0.20, 4.74)	1.10 (0.15, 8.14)
Q3: 61.52-156.50	0.14 (0.01, 1.63)	– <sup>b</sup>	0.19 (0.04, 0.96)	0.12 (0.01, 0.98)	0.20 (0.04, 1.00)	0.12 (0.01, 0.98)
Q4: >156.50	4.69 (0.75, 29.27)	7.75 (1.01, 59.66)	4.35 (1.13, 16.69)	5.93 (1.18, 29.75)	4.67 (1.24, 17.55)	6.27 (1.27, 31.04)
<i>p</i> -trend	0.008*	0.001*	0.0001*	0.0005*	0.005*	0.0004*

<sup>a</sup> *t,t*-MA has been weighted using specific sample weights for the subsample, WTVOC2PP, as recommended by NCHS [21]. Model 1 adjusted for age, sex, people from racial and ethnic groups, poverty income ratio (PIR), body weight status (normal/underweight, overweight, and obesity), self-reported ear infection, loud noise exposure and urinary creatinine. Model 2 is model 1 plus serum cotinine. <sup>b</sup>Adjusted OR was not possible because there are zero cases in the third quartile. \*Indicates associations with statistical significance (*p*<0.05).